

Remarks

With the present amendment, claims 2-10, 12, and 14-16 have been canceled without prejudice or disclaimer. Claims 25-76 (encompassing Gene No. 13 polypeptides) have been added to assist in expediting prosecution of the present application and to expand the embodiments of the elected subject matter. Hence, claims 1, 11, 13, 17-76 are currently pending in the present application.


Support for new claims 25-76 can be found in the application and claims as originally filed. In particular, support for new claims 25-76 can be found, for example, in the specification at: page 64, third row from bottom of Table 1 and at pages 69-71 (e.g. HEMCM42 ATCC Deposit, HEMCM42 amino acids 1-121, HEMCM42 amino acids 19-121); pages 71-72 (secreted portion); pages 72-77 (90% and 95% identity); page 78, lines 30-31 (30 and 50 contiguous amino acids); page 137 to page 139 (Example 23) (pharmaceutical compositions); page 80, line 21 to page 81, line 37, and pages 115-116 (Example 9) (heterologous proteins); page 83, lines 21-25 (minus methionine); and, pages 108-115 (Examples 5-8) (polypeptide production).

Conclusion

Applicants respectfully request that the above-made amendments and remarks be entered and made of record in the file history of the instant application. If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136 that is not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date: February 19, 2002


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (telephone)

JMM/DS

B